Boundless Bio, Inc. cotiza a 2.55 USD y tiene una capitalización bursátil de $59M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients wit…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-1.06 | $-0.60 | $-0.58 | $-0.62 |
| Estimado | $-0.58 | $-0.56 | $-0.52 | $-0.58 |
| Sorpresa | -82.8% | -7.1% | -11.5% | -6.9% |
| Métrica | BOLD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -59.0% | -40.4% | -18.6% |
| ROA | -37.0% | -32.0% | -5.0% |
| Current Ratio | 8.74 | 2.84 | +5.90 |
| Debt / Equity | — | 0.28 | — |